Who owns Starling Oncology, Inc. (STLN)? Elite investor 13F holders
2 tracked elite investors reported holding Starling Oncology, Inc as of 2026-06-30, including Renaissance Technologies LLC, Oasis Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Health Care Equipment & Services
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Kanen Wealth Management | THE ONCOLOGY INSTITUTE INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Renaissance Technologies LLC | THE ONCOLOGY INSTITUTE INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 7416908.00 USD | 1365913.000000 | Shares | add | Original filing |
| Oasis Management | THE ONCOLOGY INSTITUTE INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 543000.00 USD | 100000.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.